Outcomes from a prospectively implemented protocol using apixaban after robot-assisted radical cystectomy.
apixaban
bladder cancer
enoxaparin
prophylaxis
radical cystectomy
robotic surgery
venous thromboembolism
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
22
9
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
To compare the safety and efficacy of oral apixaban with that of injectable enoxaparin after robot-assisted radical cystectomy (RARC) for venous thromboembolism (VTE) thromboprophylaxis. We conducted a retrospective review of prospectively collected data for all RARC patients treated at our tertiary care centre between 2018 and 2022. The study included two groups: patients who were subject to a prospectively implemented protocol from October 2021 to the present, comprising a 21-day postoperative course of apixaban 2.5 mg twice daily after discharge, and patients treated prior to October 2021 who received enoxaparin 40 mg daily. Baseline demographics and clinical characteristics, such as VTE (defined as deep vein thrombosis and pulmonary embolism), were analysed. The primary outcome was incidence of symptomatic VTE confirmed with definitive imaging within 90 days of RARC. Secondary outcomes included major bleeding, complications, readmission, and mortality within 30 days postoperatively. Descriptive statistics included baseline patient characteristics, operative information and complications. Differences in baseline characteristics and postoperative data were compared between groups. Multivariate logistic regression was used to determine associations between variables and the primary outcome. A total of 124 patients received apixaban and 250 patients received enoxaparin prophylaxis. Ten patients (2.7%) experienced a VTE within 90 days postoperatively (two [1.6%] apixaban group vs eight [3.2%] enoxaparin group; P = 0.5). After patient stratification into European Association of Urology risk groups, no statistically significant difference in VTE rates was seen between groups in the apixaban (2.7% high- + intermediate-risk group vs 1.1% low-risk group; P = 0.5) and enoxaparin cohorts (4.3% high- + intermediate-risk group vs 2.5% low-risk group; P = 0.5). On multivariate logistic regression, no variables were associated with the development of the primary outcome. Prophylaxis with apixaban and enoxaparin showed no statistically significant differences in VTE rates among RARC patients. Apixaban appears to be safe and effective for VTE prophylaxis after RARC.
Substances chimiques
Enoxaparin
0
Anticoagulants
0
apixaban
3Z9Y7UWC1J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-396Informations de copyright
© 2023 BJU International.
Références
Lenis AT, Lec PM, Chamie K, Mshs M. Bladder cancer: a review. JAMA 2020; 324: 1980
Witjes JA, Bruins HM, Carrion A et al. EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer published at the 38th Annual Congress Milan 2023. European Association of Urology Guidelines Office, Arhem, the Netherlands. https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
Sun AJ, Djaladat H, Schuckman A, Miranda G, Cai J, Daneshmand S. Venous thromboembolism following radical cystectomy: significant predictors, comparison of different anticoagulants and timing of events. J Urol 2015; 193: 565-9
Elsayed AS, Ozair S, Iqbal U et al. Prevalence and predictors of venous thromboembolism after robot-assisted radical cystectomy. Urology 2021; 149: 146-53
VanDlac AA, Cowan NG, Chen Y et al. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. J Urol 2014; 191: 943-7
Alberts BD, Woldu SL, Weinberg AC, Danzig MR, Korets R, Badani KK. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology 2014; 84: 799-807
Rosen G, Anwar T, Syed J et al. Initial experience with apixaban for extended venous thromboembolism prophylaxis after radical cystectomy. Eur Urol Focus 2022; 8: 480-2
Catto JWF, Khetrapal P, Ricciardi F et al. Effect of robot-assisted radical cystectomy with Intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA 2022; 327: 2092-103
Babjuk M, Böhle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71: 447-61
Forrest JB, Clemens JQ, Finamore P et al. AUA best practice statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol 2009; 181: 1170-7
Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in nonorthopedic surgical patients. Chest 2012; 141: e227S-77S
Pariser JJ, Pearce SM, Anderson BB et al. Extended duration enoxaparin decreases the rate of venous thromboembolic events after radical cystectomy compared to inpatient only subcutaneous heparin. J Urol 2017; 197: 302-7
Felder S, Rasmussen MS, King R et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev 2018; 11: CD004318
Ortiz RM, Golijanin B, O'Rourke TK et al. Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single Academic Medical Center. Urology 2021; 156: 154-62
Westerman ME, Bree KK, Msaouel P et al. Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study. J Urol 2022; 208: 886-95
Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15
Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98
Chan KG, Guru K, Wiklund P et al. Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena consensus panel. Eur Urol 2015; 67: 423-31
Collins JW, Patel H, Adding C et al. Enhanced recovery after robot-assisted radical cystectomy: EAU robotic urology section scientific working group consensus view. Eur Urol 2016; 70: 649-60
Tikkinen KAO, Cartwright R, Gould MK et al. EAU Guidelines on Thromboprophylaxis in Urological Surgery published at the 37th Annual Congress Amsterdam 2022. European Association of Urology Guidelines Office, Arhem, the Netherlands. https://uroweb.org/guidelines/thromboprophylaxis
Clavien PA, Barkun J, de Oliveira ML et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96
Carson JL, Guyatt G, Heddle NM et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016; 316: 2025-35
Guntupalli SR, Brennecke A, Behbakht K et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020; 3: e207410
Schomburg J, Krishna S, Soubra A et al. Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. Urol Oncol 2018; 36: 77.e9-77.e13
Tully KH, Krimphove MJ, Reese SW et al. Trends in adherence to thromboprophylaxis guideline in patients undergoing radical cystectomy. Urology 2020; 135: 44-9
GoodRx. Prescription Prices, Coupons & Pharmacy Information. https://www.goodrx.com/. Accessed February 2023
Gulati S, Eckman MH. Anticoagulant therapy for cancer-associated thrombosis: a cost-effectiveness analysis. Ann Intern Med 2023; 176: 1-9
Dall CP, Shaw N, Egan J et al. Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy. Urol Oncol 2020; 38: 849.e19-23
Hardy T, Upchurch E, Duff H, Davenport K. Post-operative use of low molecular weight heparin: are patients doing their bit? J Clin Urol 2016; 9: 162-5
Khorana AA, McCrae KR, Milentijevic D et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost 2017; 1: 14-22
Gregson J, Kaptoge S, Bolton T et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4: 163-73